Vontobel Holding Ltd. Purchases 14,808 Shares of Pfizer Inc. $PFE

Vontobel Holding Ltd. increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 2.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 736,235 shares of the biopharmaceutical company's stock after buying an additional 14,808 shares during the quarter. Vontobel Holding Ltd.'s holdings in Pfizer were worth $17,846,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of PFE. Pacer Advisors Inc. lifted its position in shares of Pfizer by 856.8% during the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock worth $508,164,000 after buying an additional 17,957,928 shares during the period. Amundi lifted its position in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock worth $1,265,277,000 after buying an additional 15,758,846 shares during the period. Nuveen LLC bought a new position in shares of Pfizer during the 1st quarter worth approximately $389,861,000. Goldman Sachs Group Inc. lifted its position in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock worth $670,407,000 after buying an additional 9,041,990 shares during the period. Finally, Vanguard Group Inc. increased its holdings in Pfizer by 0.9% during the 1st quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company's stock valued at $13,257,004,000 after purchasing an additional 4,629,976 shares in the last quarter. Institutional investors own 68.36% of the company's stock.

Pfizer Trading Down 1.8%

Shares of PFE opened at $25.22 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.08. The firm has a market capitalization of $143.39 billion, a PE ratio of 13.41, a price-to-earnings-growth ratio of 0.84 and a beta of 0.55. The stock's fifty day simple moving average is $24.83 and its 200-day simple moving average is $24.14.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the prior year, the firm posted $0.60 earnings per share. The firm's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.8%. Pfizer's dividend payout ratio (DPR) is presently 91.49%.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on PFE. Wall Street Zen cut Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Bank of America raised their price target on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday, October 3rd. Morgan Stanley raised their price target on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. UBS Group reaffirmed a "neutral" rating and set a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Finally, Citigroup raised their price target on Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus price target of $28.41.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.